The Sunshine Reporter

Delveinsight Business Research LLP

Some of the key players such as Geron (Imetelstat), AbbVie (Navitoclax), Sierra Oncology (Momelotinib), Incyte Corporation (Parsaclisib), Celgene/BMS (Luspatercept-aamt), MorphoSys (Pelabresib), Imago Biosciences (Bomedemstat), Pharmaxis (PXS-5505), and others are evaluating their lead candidates in different stages of clinical development.

As per DelveInsight, the Myelofibrosis therapeutics market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Myelofibrosis, extensive research and development activities of pharmaceutical companies and the expected launch of pipeline therapies in the market. Upcoming therapies are focusing on different mechanisms other than JAK inhibitors, such as imetelstat (telomerase inhibitor), navitoclax (BCL-XL/BCL-2 inhibitor), GB2064 (LOXL2 protein inhibitors), navtemadlin (MDM2 protein inhibitor), pelabresib (BET inhibitor), and others which may cover the patient need in refractory and relapse to JAK inhibitor and provide an alternative treatment for the patients.

“Myelofibrosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Myelofibrosis Market. 

The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Myelofibrosis Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Myelofibrosis and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Myelofibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

Molecule Type

The report covers the pipeline products that have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Myelofibrosis Therapeutic Segment @

https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

Myelofibrosis Therapeutics Landscape

Several major pharma and biotech giants are developing therapies for Myelofibrosis. Currently,  Incyte Corporation is leading the therapeutics market with its Myelofibrosis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Myelofibrosis Therapeutics Market Include:

AbbVie, Actuate Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Cellenkos, Galecto Biotech, Geron Corporation, Imago BioSciences, Incyte Corporation, iOnctura, Jacobio Pharmaceuticals, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Menarini Group, MorphoSys, Nippon Shinyaku, Novartis Oncology, NS Pharma, Ohm oncology, PharmaEssentia, Pharmaxis, Roche, Secura Bio, Sierra Oncology, Sumitomo Pharma Oncology, Telios Pharma, and others. 

Myelofibrosis Emerging and Marketed Therapies Covered in the Report Include:

• Imetelstat: Geron Corporation

• IOA-244: iOnctura

• KER-050: Keros Therapeutics

• Momelotinib: Sierra Oncology

• Navitoclax (ABT-263): AbbVie

• NS-018: Nippon Shinyaku

• Parsaclisib (INCB050465): Incyte

• PXS-5505: Pharmaxis

• REBLOZYL (Luspatercept/ACE-536): Celgene/Bristol Myers Squibb

• TP-3654: Sumitomo Pharma Oncology

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Myelofibrosis Current Treatment Patterns

4. Myelofibrosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Myelofibrosis Late Stage Products (Phase-III)

7. Myelofibrosis Mid-Stage Products (Phase-II)

8. Myelofibrosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Myelofibrosis Discontinued Products

13. Myelofibrosis Product Profiles

14. Key Companies in the Myelofibrosis Market

15. Key Products in the Myelofibrosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Myelofibrosis Unmet Needs

18. Myelofibrosis Future Perspectives

19. Myelofibrosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/